Plain-English translation of NCT06860594 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage trial testing a drug called combined with radiation therapy for people whose brain tumors (glioblastoma or astrocytoma) have come back after previous treatment. Researchers want to find the safest and most effective dose of the medication when given alongside radiation, and to see how well this combination works at controlling tumor growth.
Recurring brain tumors are difficult to treat, and standard options are often limited. This medication may help radiation therapy work better, potentially giving patients a new option when their tumors return.
You likely qualify if…
You likely don't qualify if…
You would receive 10 radiation therapy sessions over 2 weeks (Monday through Friday), and take the study medication by mouth 2 hours before each radiation session. You would have imaging scans (CT or MRI) and blood tests at various points during and after treatment to check how well the treatment is working and monitor for side effects. After treatment ends, you would return for a follow-up visit 2 weeks later, then every 3 months for up to 5 years.
AI-generated summary from trial data · Aug 21, 2026 · Not medical advice
United States